Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Interest Expense

Cost of servicing the company's debt during the period.

Dyadic International, Inc.NASDAQ: DYAI

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense declines year over year

Q1 FY2026 interest expense of $109.18K fell 3.9% year over year, ahead of the -16.8% change in trailing-twelve-month interest expense. Sequentially, it fell 4.6% from the prior quarter.

Context

  • Interest expense amounted to 37.0% of revenue in FY2025, up 24.8 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -3.9% holds above the trailing-twelve-month pace of -16.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$109.18K-4.6% QoQ
Last fiscal yearDec 2025
$455.9K+6.5% YoY
LTMMar 2026
$423.34K-16.8% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.9%——
1 year+6.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
455.9K USD
Year-over-year change
+6.5%

Interest Expense vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.8% is the 2nd highest of 6, against a peer median of -100.0%.
  • Interest expense amounts to 14.2% of revenue for DYAI, versus a peer median of 0.0%.
DYAI Competitors
Interest Expense for DYAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$6.75M USD+7.8%—25.4%
PYPDPolyPid Ltd.LTM Mar 2026$545K USD-63.4%-20.0%—
DYAIDyadic International, Inc.LTM Mar 2026$423.34K USD-16.8%—14.2%
ATHEAlterity Therapeutics LimitedFY2025A$0 AUD——0.0%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 USD-100.0%——
VERUVeru Inc.LTM Mar 2026$0 USD-100.0%——
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD-100.0%——
RNXTRenovoRx, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding DYAI) —-100.0%-20.0%0.0%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.